登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，1月12日，Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2021-02-08

  • Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
    Paul-Albert Koenig1,2,*, View ORCID ProfileHrishikesh Das3,†, View ORCID ProfileHejun Liu4,†, Beate M. Kümmerer5,6, View ORCID ProfileFlorian N. Gohr2,‡, View ORCID ProfileLea-Mar...

    Science  12 Jan 2021:
    eabe6230
    DOI: 10.1126/science.abe6230

    Abstract
    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread with devastating consequences. For passive immunization efforts, nanobodies have size and cost advantages over conventional antibodies. Here, we generated four neutralizing nanobodies that target the receptor-binding domain of the SARS-CoV-2 spike protein. We defined two distinct binding epitopes using x-ray crystallography and cryo-electron microscopy. Based on the structures, we engineered multivalent nanobodies with more than 100-fold improved neutralizing activity than monovalent nanobodies. Biparatopic nanobody fusions suppressed the emergence of escape mutants. Several nanobody constructs neutralized through receptor-binding competition, while other monovalent and biparatopic nanobodies triggered aberrant activation of the spike fusion machinery. These premature conformational changes in the spike protein forestalled productive fusion, and rendered the virions non-infectious.

  • 原文来源：https://science.sciencemag.org/content/early/2021/01/11/science.abe6230
34浏览量
原文链接
相关报告

  • 《Science，5月1日，SARS-CoV-2 productively infects human gut enterocytes》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-03
    • SARS-CoV-2 productively infects human gut enterocytes Mart M. Lamers1,*, Joep Beumer2,*, Jelte van der Vaart2,*, Kèvin Knoops3, Jens Puschhof2, Tim I. Breugem1, Raimond B. G. Ravelli3, J. Paul van Schayck3, Anna Z. Mykytyn1, Hans Q. Duimel3, Elly van Donselaar3, Samra Riesebosch1, Helma J. H. Kuijpers3, Debby Schippers1, Willine J. van de Wetering3, Miranda de Graaf1, Marion Koopmans1, Edwin Cuppen4,5, Peter J. Peters3, Bart L. Haagmans1,†, Hans Clevers2,†,‡ See all authors and affiliations Science 01 May 2020: eabc1669 DOI: 10.1126/science.abc1669 Abstract The virus severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) can cause coronavirus disease 2019 (COVID-19), an influenza-like disease that is primarily thought to infect the lungs with transmission via the respiratory route. However, clinical evidence suggests that the intestine may present another viral target organ. Indeed, the SARS-CoV-2 receptor angiotensin converting enzyme 2 (ACE2) is highly expressed on differentiated enterocytes. In human small intestinal organoids (hSIOs), enterocytes were readily infected by SARS-CoV and SARS-CoV-2 as demonstrated by confocal- and electron-microscopy. Consequently, significant titers of infectious viral particles were detected. mRNA expression analysis revealed strong induction of a generic viral response program. Hence, intestinal epithelium supports SARS-CoV-2 replication, and hSIOs serve as an experimental model for coronavirus infection and biology
    74浏览量
    原文链接

  • 《Science，12月4日，Robust neutralizing antibodies to SARS-CoV-2 infection persist for months》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-12-22
    • Robust neutralizing antibodies to SARS-CoV-2 infection persist for months View ORCID ProfileAnia Wajnberg1,*, View ORCID ProfileFatima Amanat2,3, Adolfo Firpo4, View ORCID ProfileDeena R. Altman5, Mark J. Bailey1, View ORCID ProfileMayce Mansour1,... Science  04 Dec 2020: Vol. 370, Issue 6521, pp. 1227-1230 DOI: 10.1126/science.abd7728 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.
    18浏览量
    原文链接